Bicycle Therapeutics Reports Positive Phase 2 Duravelo-2 Data for Zelenectide in Urothelial Cancer

summarizeSummary

Bicycle Therapeutics announced positive Phase 2 data for its zelenectide program in metastatic urothelial cancer, showing comparable efficacy to existing treatments with a better safety profile.

check_boxKey Events

• Positive Phase 2 Data

  Initial Duravelo-2 data for zelenectide pevedotin in metastatic urothelial cancer showed overall response rates (ORR) of 58-62% in combination with pembrolizumab, comparable to standard of care.

• Differentiated Safety Profile

  Zelenectide demonstrated significantly lower rates of skin reactions (approximately four-fold lower) and peripheral neuropathy (half the incidence) compared to published data for standard of care, suggesting improved tolerability.

• Pipeline Re-evaluation Potential

  This positive data for zelenectide, a program previously deprioritized in March 2026, could lead to a re-evaluation of its strategic importance, especially given the stock's current trading near 52-week lows.

• Further Data Expected

  Additional data from the randomized Phase 2 Duravelo-2 trial are anticipated in the second half of 2026.

auto_awesomeAnalysis

This filing announces encouraging Phase 2 clinical data for zelenectide pevedotin in metastatic urothelial cancer, demonstrating response rates comparable to standard of care but with a potentially superior safety profile. This positive development for a program previously subject to deprioritization could significantly impact the company's pipeline strategy and investor sentiment, especially with the stock trading near 52-week lows.